Evaluating Risks, Costs, and Benefits of New and Emerging Therapies to Optimize Outcomes in Multiple Sclerosis

Journal of Managed Care Pharmacy
doi 10.18553/jmcp.2012.18.s9-b.1
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Academy of Managed Care Pharmacy

Related search

Risks vs Benefits of Glatiramer Acetate: A Changing Perspective as New Therapies Emerge for Multiple Sclerosis

Therapeutics and Clinical Risk Management
2010English

Emerging Therapies for Relapsing Multiple Sclerosis

Archives of Neurology
2009English

Multiple Sclerosis and Complementary Therapies

Journal of Academic Research in Nursing
2019English

Systemic Sclerosis Pathogenesis and Emerging Therapies, Beyond the Fibroblast

BioMed Research International
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2019English

Evaluating the Risks and Benefits of Participation in High-School Football

AMA journal of ethics
Health PolicyEthicsHealthIssuesLegal Aspects
2014English

Benefits, Risks and Costs of Immunization for Measles, Mumps and Rubella.

American Journal of Public Health
EnvironmentalPublic HealthOccupational Health
1985English

Emerging Immunopharmacological Targets in Multiple Sclerosis

Journal of the Neurological Sciences
Neurology
2015English

New Insights Into the Burden and Costs of Multiple Sclerosis in Europe: Results for Sweden

Multiple Sclerosis
Neurology
2017English

New Insights Into the Burden and Costs of Multiple Sclerosis in Europe: Results for Switzerland

Multiple Sclerosis
Neurology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy